Paul Maher

Shareholder, Vice Chair

Paul Maher serves as a Vice Chair of Greenberg Traurig. He concentrates on corporate law, particularly cross-border public and private mergers and acquisitions. He advises a wide range of domestic and international clients in numerous sectors, including chemicals, pharmaceuticals, life sciences, financial services, information services, retail and communications.

Paul is highly recommended by both of the leading independent guides to the legal industry. In its 2017 edition, Chambers UK stated that Paul is highly touted by clients as "a class act" who provides "very insightful" advice and is "driven to do the best,” while the Legal 500 UK highlighted that Paul is "a skilled negotiator with a commercial mindset" in its 2016 edition.

Concentrations

  • Chemicals, pharmaceuticals, biotechnology, agrochemicals
  • Entertainment / music industry
  • Communications
  • Banking
Read More +

Capabilities

Experience

  • Advised Smiths Group plc on the sale of Smiths Interconnect’s Microwave Telecoms business to Infinite Electronics Incfor US$112.5m.
  • Advised Rentokil Initial plc on its joint venture agreement with Haniel & Cie. Holding Company which created a leading provider of workwear and hygiene services in Europe with combined revenues of c. €1.1bn.
  • Advised Rentokil Initial plc on its joint venture with PCI Pest Control Pvt. Ltd., creating the largest provider of pest control services and products in India.
  • Advised AstraZeneca plc on the sale of its small molecule antibiotics business to Pfizer for US$725m.
  • Advised AB Volvo on the sale of its North American construction equipment rental business to Platinum Equity for $1.1bn.
  • Advised Rentokil Initial plc on the sale of its Initial Facilities business to Interserve plc for £250m.
  • Advised AB Volvo on the sale of its Volvo Aero aircraft engines business to GKN (Holdings) plc for £700m.
  • Advised AstraZeneca plc on its US$1.15bn (£740m) acquisition of Pearl Therapeutics, a privately held US company developing inhaled combination therapies for the treatment of respiratory diseases.
  • Advised Rentokil Initial plc on its sale of City Link Limited to BECAP12 Fund LP (Better Capital), a private equity investor.
  • Advised AstraZeneca plc on its agreement to sell its AstraTech business to Dentsply for $1.8bn.
  • Advised Smiths Group plc in relation to its joint venture with Analogic. 
  • Advised Healthcor, 3i and senior management of ApaTech Limited in its US$330m sale to global health care company Baxter International Inc.
  • Advised Dutch food company Vion in its purchase of a majority shareholding in J&J Tranfield. 
  • Advised AstraZeneca plc in connection with its equity investment in the AIM-listed Silence Therapeutics. 
  • Advised AstraZeneca plc and its subsidiary Cambridge Antibody Technology Limited in the disposal by CAT of its Humira® royalty stream to Royalty Pharma.
  • Advised shareholders of The Mergermarket Group on their agreement to sell the entire issued share capital of Pearson plc.
  • Advised Imperial Chemical Industries plc (ICI) on its agreement to sell its Uniqema manufacturing to Croda International plc.
  • Advised Bear Stearns and its subsidiary BSG Insurance Holdings on the acquisition of Minster Insurance Services from Groupama UK for an undisclosed sum. 
  • Advised senior management on the sale of Financial Dynamics to FTI Consulting Inc.
  • Advised Cambridge Antibody Technology Group plc on its recommended cash offer by AstraZeneca for its entire issued and to-be-issued share capital. 
  • Advised Etex SA on the disposal of its Thermalite division to Hanson.
  • Advised Danske Bank on its acquisition of Northern Bank and National Irish Bank from National Australia Bank. 
  • Advised Wittington Investments on its recommended offer for Selfridges plc. 
  • Advised ICI plc on the sale of the U.S., Canadian and European Vinamul Polymers business National Starch and Chemical (NSC) Company to Celanese. (NSC is a business unit of ICI.)
  • Advised GE on its recommended offer for Druck Holdings plc. 
  • Advised Cable & Wireless plc on its purchase of UK-based broadband service provider Bulldog Communications Limited. 
  • Advised Monsanto Company and its subsidiaries on the disposal of its European wheat and barley seed business to RGAT Genetique S.A.
  • Advised Cambridge Antibody Technology Group plc on its proposed takeover of Oxford GlycoSciences plc to be effected by way of a scheme of arraignment.

°Certain of the above representations were handled by Mr. Maher prior to his joining Greenberg Traurig, LLP.

  • In-house lawyer, Imperial Chemical Industries (ICI) PLC, 1984-1990

Recognition & Leadership

  • Listed, IFLR 1000 United Kingdom, "Leading Lawyers – M&A," 2017
  • Listed, Chambers UK Guide, Corporate/M&A, 2012-2017
  • Listed, Chambers Global, Corporate/M&A (UK), 2012-2017
  • Listed, The Legal 500 United Kingdom, Corporate and Commercial – M&A: Upper Mid-Market and Premium Deals, 2011-2016
  • Listed, Super Lawyers magazine, London Super Lawyers, 2013-2014
  • Member, Winning Team, M&A Deal of the Year (Over US$1 Billion), M&A Advisor Awards, 2013
  • Member, Winning Team, Consumer and Retail Products Deal of the Year (Over US$1 Billion), M&A Advisor Awards, 2013
  • Shortlisted, The Lawyer Awards, "Partner of the Year", 2010
  • Recipient, The Lawyer Awards, “Partner of the Year”, 2007
  • Listed, Management, ”The Lawyer’s Hot 100 Survey”, January 2003 and 2007 
  • Listed, UK Financial Times, one of the three most innovative lawyers, "Survey of Innovative Lawyers", June 2006 
  • Listed, PLC Which Lawyer?

Credentials

Education
  • LL.B., Bristol University
Admissions
  • England and Wales